Drug-induced nephrotoxicity
Overview
•Type IV (delayed) hypersensitivity reaction - drug or metabolite acts as hapten, triggering T-lymphocyte and eosinophil infiltration of the renal interstitium
•Onset typically 7-10 days after first exposure (shorter on re-exposure)
•Most common cause: penicillins (especially amoxicillin); PPIs are an increasingly recognised cause with more insidious onset
•Classic triad: fever + rash + arthralgia - present in only ~30% of cases
•More consistently found: eosinophilia, sterile pyuria, (eosinophiluria)
•Hyperkalaemia is the most common electrolyte abnormality - impaired tubular potassium excretion
Investigations
🥇 First-line
•U&E (creatinine, eGFR, hyperkalaemia), FBC (eosinophilia), urine dipstick/microscopy (sterile pyuria, eosinophiluria in AIN; muddy brown casts in ATN)
•If nephrogenic DI suspected: serum and urine osmolality; water deprivation test then desmopressin - nephrogenic DI shows no rise in urine osmolality after desmopressin
•Drug levels: lithium and aminoglycoside levels - essential for monitoring toxicity
🏆 Gold standard
•renal biopsy - confirms AIN (interstitial oedema, tubulitis, eosinophil/T-lymphocyte infiltration); reserved for diagnostic uncertainty or failure to recover
Lithium-induced Nephrogenic Diabetes Insipidus
•Lithium enters collecting duct cells via sodium channels and desensitises the renal response to ADH - interferes with V2 receptor signalling and downregulates aquaporin-2 water channels
•Result: inability to concentrate urine regardless of ADH levels
•Presents with polyuria (>3 L/day) and polydipsia; raised serum osmolality, low urine osmolality
•No response to *desmopressin - distinguishes nephrogenic DI from central DI (which does respond) and psychogenic polydipsia (urine concentrates after water deprivation alone)
Other Key Drug-Kidney Mechanisms
Drug-induced nephrotoxicity patterns
| Drug/class | Mechanism | Key finding |
|---|---|---|
| NSAIDs | Block prostaglandin-mediated afferent vasodilation → ↓ intraglomerular pressure → ↓ GFR; especially dangerous in low-perfusion states | Pre-renal AKI; bland urine |
| ACE inhibitors / ARBs | Block efferent arteriolar constriction → ↓ intraglomerular pressure; critical risk in bilateral renal artery stenosis | Pre-renal AKI; hyperkalaemia |
| Aminoglycosides (e.g. ***gentamicin***) | Accumulate in proximal tubular cells via megalin receptors → reactive oxygen species → apoptosis (ATN) | Muddy brown granular casts; monitor trough levels |
| ***Cisplatin*** | Direct DNA cross-linking in proximal tubular cells + peritubular vasoconstriction → ATN | Muddy brown casts; electrolyte wasting |
| ***Amoxicillin*** / penicillins | Type IV hypersensitivity → T-cell/eosinophil interstitial infiltration → AIN | Fever, rash, arthralgia, eosinophilia, sterile pyuria |
| ***Lithium*** | Desensitises ADH response; downregulates aquaporin-2 → nephrogenic DI | Polyuria, polydipsia; no response to desmopressin |
Management and Prevention
•Cornerstone: stop the causative drug as early as possible
•AIN: stop culprit drug, ensure adequate hydration, monitor U&E; if creatinine fails to improve within 1-2 weeks consider oral prednisolone
•Aminoglycosides: use once-daily dosing regimens to minimise tubular accumulation; therapeutic drug monitoring